These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 35493526)

  • 1. Research Progress of Biomarkers for Immune Checkpoint Inhibitors on Digestive System Cancers.
    Wang J; Ma X; Ma Z; Ma Y; Wang J; Cao B
    Front Immunol; 2022; 13():810539. PubMed ID: 35493526
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Microsatellite instability and immune checkpoint inhibitors: toward precision medicine against gastrointestinal and hepatobiliary cancers.
    Eso Y; Shimizu T; Takeda H; Takai A; Marusawa H
    J Gastroenterol; 2020 Jan; 55(1):15-26. PubMed ID: 31494725
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification and Utilization of Biomarkers to Predict Response to Immune Checkpoint Inhibitors.
    Gjoerup O; Brown CA; Ross JS; Huang RSP; Schrock A; Creeden J; Fabrizio D; Tolba K
    AAPS J; 2020 Oct; 22(6):132. PubMed ID: 33057937
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictive biomarkers in PD-1/PD-L1 checkpoint blockade immunotherapy.
    Meng X; Huang Z; Teng F; Xing L; Yu J
    Cancer Treat Rev; 2015 Dec; 41(10):868-76. PubMed ID: 26589760
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Robust Prediction of Immune Checkpoint Inhibition Therapy for Non-Small Cell Lung Cancer.
    Jiang J; Jin Z; Zhang Y; Peng L; Zhang Y; Zhu Z; Wang Y; Tong D; Yang Y; Wang J; Yang Y; Xiao K
    Front Immunol; 2021; 12():646874. PubMed ID: 33927719
    [TBL] [Abstract][Full Text] [Related]  

  • 6. News on immune checkpoint inhibitors as immunotherapy strategies in adult and pediatric solid tumors.
    Melaiu O; Lucarini V; Giovannoni R; Fruci D; Gemignani F
    Semin Cancer Biol; 2022 Feb; 79():18-43. PubMed ID: 32659257
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pan-cancer analysis of ARID family members as novel biomarkers for immune checkpoint inhibitor therapy.
    Zhu Y; Yan C; Wang X; Xu Z; Lv J; Xu X; Yu W; Zhou M; Yue L
    Cancer Biol Ther; 2022 Dec; 23(1):104-111. PubMed ID: 35239432
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The emerging role of immunotherapy in biliary tract cancer: a review of new evidence and predictive biomarkers.
    Giorgione R; Risaliti M; Bartolini I; Rossi G; Pillozzi S; Muiesan P; Taddei A; Antonuzzo L
    Immunotherapy; 2022 May; 14(7):567-576. PubMed ID: 35382560
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Emerging biomarkers for immunotherapy response in biliary tract cancers: a comprehensive review of immune checkpoint inhibitor strategies.
    Lou Y; Chen Y; Guo K; Li B; Zheng S
    Biomark Med; 2024; 18(15-16):703-715. PubMed ID: 39143949
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunotherapy for Colorectal Cancer.
    Mukherji R; Weinberg BA; Pedersen KS
    Hematol Oncol Clin North Am; 2022 Jun; 36(3):603-626. PubMed ID: 35577706
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The LIPI score and inflammatory biomarkers for selection of patients with solid tumors treated with checkpoint inhibitors.
    Benitez JC; Recondo G; Rassy E; Mezquita L
    Q J Nucl Med Mol Imaging; 2020 Jun; 64(2):162-174. PubMed ID: 32107903
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The biomarkers of hyperprogressive disease in PD-1/PD-L1 blockage therapy.
    Wang X; Wang F; Zhong M; Yarden Y; Fu L
    Mol Cancer; 2020 May; 19(1):81. PubMed ID: 32359357
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune Checkpoint Inhibitors: A Promising Treatment Option for Metastatic Castration-Resistant Prostate Cancer?
    Ruiz de Porras V; Pardo JC; Notario L; Etxaniz O; Font A
    Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33946818
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunotherapy and predictive immunologic profile: the tip of the iceberg.
    Cunha Pereira T; Rodrigues-Santos P; Almeida JS; Rêgo Salgueiro F; Monteiro AR; Macedo F; Soares RF; Domingues I; Jacinto P; Sousa G
    Med Oncol; 2021 Mar; 38(5):51. PubMed ID: 33788049
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cell-free DNA copy number variations predict efficacy of immune checkpoint inhibitor-based therapy in hepatobiliary cancers.
    Yang X; Hu Y; Yang K; Wang D; Lin J; Long J; Xie F; Mao J; Bian J; Guan M; Pan J; Huo L; Hu K; Yang X; Mao Y; Sang X; Zhang J; Wang X; Zhang H; Zhao H
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33972389
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current status and perspectives of immune checkpoint inhibitors for colorectal cancer.
    Hirano H; Takashima A; Hamaguchi T; Shida D; Kanemitsu Y;
    Jpn J Clin Oncol; 2021 Jan; 51(1):10-19. PubMed ID: 33205813
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Blood-based Biomarkers in the Immune Checkpoint Inhibitor Treatment in 
Non-small Cell Lung Cancer].
    Wang P; Tang C; Liang J
    Zhongguo Fei Ai Za Zhi; 2021 Jul; 24(7):503-512. PubMed ID: 34187157
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current status of immune checkpoint inhibitors for gastric cancer.
    Kono K; Nakajima S; Mimura K
    Gastric Cancer; 2020 Jul; 23(4):565-578. PubMed ID: 32468420
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimizing cancer immunotherapy: Is it time for personalized predictive biomarkers?
    Music M; Prassas I; Diamandis EP
    Crit Rev Clin Lab Sci; 2018 Nov; 55(7):466-479. PubMed ID: 30277835
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predicting immunotherapy response through genomics.
    Cormedi MCV; Van Allen EM; Colli LM
    Curr Opin Genet Dev; 2021 Feb; 66():1-9. PubMed ID: 33307238
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.